TNF-α and IFN-γ treatment was found to increase the transcriptional activity of NF-κB through the MAPK/STAT1 signaling pathway and to promote AD through the phosphorylation of NF-κB. This evidence concerns the gene NFKB1 and Alzheimer disease.